publication . Article . 2017

новые возможности иммунотерапии в лечении распространенного рецидивного плоскоклеточного рака органов головы и шеи

A. M. Mudunov; M. N. Narimanov; D. A. Safarov;
Open Access
  • Published: 01 Jun 2017 Journal: Head and neck tumors (HNT), volume 7, pages 99-105 (issn: 2222-1468, eissn: 2411-4634, Copyright policy)
  • Publisher: Publishing House ABV Press
Abstract
Patients with head and neck squamous cell carcinoma diagnosed with recurrent tumor or distant metastases usually have the worst prognosis. Chemotherapeutic options are very limited in these patients; there is a probability of drug resistance development. The researchers continue to search more effective and less toxic drugs. In the current article, we analyze the results of the latest randomized clinical trials devoted the assessment of novel antitumor immunotherapeutic drugs – PD-1 inhibitors – in patients with head and neck squamous cell carcinoma. This studies reveal new possibilities for the treatment of these patients.
Subjects
free text keywords: Nivolumab, Pembrolizumab, Drug resistance, Oncology, medicine.medical_specialty, medicine, Randomized controlled trial, law.invention, law, Internal medicine, Recurrent Tumor, Head and neck squamous-cell carcinoma, medicine.disease, business.industry, business, head and neck tumors, squamous cell carcinoma, pd-1, immune therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2017

новые возможности иммунотерапии в лечении распространенного рецидивного плоскоклеточного рака органов головы и шеи

A. M. Mudunov; M. N. Narimanov; D. A. Safarov;